Levels of p 53 Protein Increase with Maturation in Human Hematopoietic Cells 1

Transfection of the wild-type p53 gene into malignant cell lines usually results in an inhibition of proliferation. However, the physiological function of the endogenous p53 gene product has been difficult to ascer tain. In order to examine whether pS3 is involved in the regulation of proliferation and/or differentiation of hematopoietic tissue, we modified a recently developed flow cytometric assay to assess p53 protein expres sion in normal human hematopoietic cells, primary leukemias, and se lected leukemia cell lines. In normal human bone marrow, p53 protein was not detected in the proliferative, progenitor cell populations identified by the cell surface antigens CD34 (progenitor cells of multiple lineages) or glycophorin (erythroid precursors). In contrast, low but detectable levels of p53 protein were observed in the nonproliferative, mature lymphoid, granulocytic, and monocytic cell populations. Similarly, p53 levels increased and DNA synthesis decreased during 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of ML-1 myeloblastic leu kemia cells. Both of these results suggest that endogenous, wild-type p53 protein may play a role in hematopoietic cell maturation, possibly by contributing to the inhibition of proliferation that occurs during terminal differentiation. Leukemia cells deviated from this pattern of expression: (a) in contrast to the normal, proliferative bone marrow progenitor cells, a significant percentage of patient leukemia samples expressed detectable levels of p53 protein; and (b) leukemia cell lines exhibited lineage-specific abnormalities in p53 expression, with overexpression in lymphoid cell lines and lack of expression in myeloid cell lines.

[1]  A. Berrebi,et al.  p53 in chronic myelogenous leukemia in acute phase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Minden,et al.  Mutation of the p53 gene in human acute myelogenous leukemia. , 1991, Blood.

[4]  Koichi Sugimoto,et al.  Mutations of the p53 gene in lymphoid leukemia. , 1991, Blood.

[5]  R. Craig,et al.  Improved coupling between proliferation‐arrest and differentiation‐induction in ML‐1 human myeloblastic leukemia cells , 1990, Journal of cellular physiology.

[6]  P. Nowell,et al.  Origins of human cancer revisited , 1990, Cell.

[7]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[8]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[9]  G. Lozano,et al.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.

[10]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[11]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[14]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Schimke,et al.  Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. , 1989, Cytometry.

[16]  M. Kastan,et al.  Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. , 1989, Blood.

[17]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[18]  P. Friedman,et al.  The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen , 1989, Cell.

[19]  M. Lübbert,et al.  Expression, methylation and chromatin structure of the p53 gene in untransformed and human T-cell leukemia virus type I-transformed human T-lymphocytes. , 1989, Oncogene.

[20]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[21]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.

[22]  P. Marks,et al.  Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation. , 1989, Oncogene.

[23]  J. Lawrence,et al.  Early events in murine erythroleukemia cells induced to differentiate: variation of the cell cycle parameters in relation to p53 accumulation. , 1988, Experimental cell research.

[24]  M. Loken,et al.  Simultaneous analysis of DNA content and surface antigens in human bone marrow. , 1988, Cytometry.

[25]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[26]  J. Gamble,et al.  Evidence that immunological variants of p53 represent alternative protein conformations. , 1988, Virology.

[27]  C. Civin,et al.  Assessment of proliferation during maturation of the B lymphoid lineage in normal human bone marrow. , 1988, Blood.

[28]  J. Chirgwin,et al.  Isolation of RNA using guanidinium salts. , 1987, Methods in enzymology.

[29]  E. McCulloch,et al.  Expression of the p53 oncogene in acute myeloblastic leukemia , 1986, The Journal of experimental medicine.

[30]  J. Yewdell,et al.  Monoclonal antibody analysis of p53 expression in normal and transformed cells , 1986, Journal of virology.

[31]  V. Rotter,et al.  Expression of p53 in human leukemia and lymphoma. , 1986, Blood.

[32]  H. Koeffler,et al.  Increased expression of p53 protein in human leukemia cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. E. Sippel,et al.  Subnuclear localization of proteins encoded by the oncogene v-myb and its cellular homolog c-myb , 1986, Molecular and cellular biology.

[34]  Z. Darżynkiewicz,et al.  p53 content in relation to cell growth and proliferation in murine L1210 leukemia and normal lymphocytes. , 1986, Leukemia research.

[35]  M. Oren,et al.  p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors , 1985, Molecular and cellular biology.

[36]  W. Mercer,et al.  Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. , 1985, Experimental cell research.

[37]  J. Jenkins,et al.  Precise epitope mapping of the murine transformation‐associated protein, p53. , 1985, The EMBO journal.

[38]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Gruss,et al.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells , 1984, Nature.

[40]  J. Milner.  Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes , 1984, Nature.

[41]  R. Craig,et al.  Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells. , 1984, Cancer research.

[42]  R. Craig,et al.  Early decline in c-myb oncogene expression in the differentiation of human myeloblastic leukemia (ML-1) cells induced with 12-O-tetradecanoylphorbol-13-acetate. , 1984, Cancer research.

[43]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[44]  A. Levine,et al.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 , 1983, Molecular and cellular biology.

[45]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[46]  L. Crawford.  The 53,000-dalton cellular protein and its role in transformation. , 1983, International review of experimental pathology.

[47]  L. Old,et al.  Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Levine,et al.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells , 1981, Molecular and cellular biology.

[49]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.